Youth-onset type 2 diabetes has limited treatment options with lower glycaemic efficacy than adult-onset disease. To address this gap, a study assessed the safety and efficacy of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, versus placebo in 146 participants. The study found that tirzepatide significantly reduced HbA1c by 2.23% at week 30 compared with a 0.05% increase on placebo, with efficacy sustained through 52 weeks. Tirzepatide also lowered BMI by 7.4% and 11.2% in the 5 mg and 10 mg groups, versus 0.4% with placebo.
The most common adverse events were mild-to-moderate gastrointestinal symptoms that lessened over time, with a safety profile consistent with adults and no deaths reported. These findings suggest that tirzepatide may be an effective and well-tolerated treatment option for youth-onset type 2 diabetes. Did you find this…
